216 related articles for article (PubMed ID: 31923801)
21. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
[TBL] [Abstract][Full Text] [Related]
22. The histone demethylase PHF8 promotes adult acute lymphoblastic leukemia through interaction with the MEK/ERK signaling pathway.
Fu Y; Yang Y; Wang X; Yin X; Zhou M; Wang S; Yang L; Huang T; Xu M; Chen C
Biochem Biophys Res Commun; 2018 Feb; 496(3):981-987. PubMed ID: 29330049
[TBL] [Abstract][Full Text] [Related]
23. Histone demethylase PHF8 promotes cell growth and metastasis of non-small-cell lung cancer through activating Wnt/β-catenin signaling pathway.
Hu Y; Mu H; Yang Y
Histol Histopathol; 2021 Aug; 36(8):869-877. PubMed ID: 34100557
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic features of PHF8 histone demethylase in esophageal squamous cell carcinoma.
Sun X; Qiu JJ; Zhu S; Cao B; Sun L; Li S; Li P; Zhang S; Dong S
PLoS One; 2013; 8(10):e77353. PubMed ID: 24146981
[TBL] [Abstract][Full Text] [Related]
25. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
26. CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
Choi HJ; Jin S; Cho H; Won HY; An HW; Jeong GY; Park YU; Kim HY; Park MK; Son T; Min KW; Jang KS; Oh YH; Lee JY; Kong G
EMBO Rep; 2019 Oct; 20(10):e48058. PubMed ID: 31468695
[TBL] [Abstract][Full Text] [Related]
27. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
28. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
Singh JK; Farnie G; Bundred NJ; Simões BM; Shergill A; Landberg G; Howell SJ; Clarke RB
Clin Cancer Res; 2013 Feb; 19(3):643-56. PubMed ID: 23149820
[TBL] [Abstract][Full Text] [Related]
29. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
Baldassarre T; Truesdell P; Craig AW
Breast Cancer Res; 2017 Oct; 19(1):110. PubMed ID: 28974266
[TBL] [Abstract][Full Text] [Related]
30. Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.
Liu Y; Xu J; Choi HH; Han C; Fang Y; Li Y; Van der Jeught K; Xu H; Zhang L; Frieden M; Wang L; Eyvani H; Sun Y; Zhao G; Zhang Y; Liu S; Wan J; Huang C; Ji G; Lu X; He X; Zhang X
Nat Commun; 2018 Nov; 9(1):4718. PubMed ID: 30413718
[TBL] [Abstract][Full Text] [Related]
31. Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling.
Nakanishi T; Chumsri S; Khakpour N; Brodie AH; Leyland-Jones B; Hamburger AW; Ross DD; Burger AM
Br J Cancer; 2010 Mar; 102(5):815-26. PubMed ID: 20145614
[TBL] [Abstract][Full Text] [Related]
32. NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer.
Jiang L; Ren L; Chen H; Pan J; Zhang Z; Kuang X; Chen X; Bao W; Lin C; Zhou Z; Huang D; Yang J; Huang H; Wang L; Hou N; Song L
Cell Death Dis; 2020 Jul; 11(7):547. PubMed ID: 32683421
[TBL] [Abstract][Full Text] [Related]
33. The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression.
Lo PK; Lee JS; Liang X; Sukumar S
Cell Signal; 2016 Oct; 28(10):1502-19. PubMed ID: 27377963
[TBL] [Abstract][Full Text] [Related]
34. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Corominas-Faja B; Cufí S; Vazquez-Martin A; Martin-Castillo B; Iglesias JM; López-Bonet E; Martin ÁG; Menendez JA
Cell Cycle; 2012 Nov; 11(21):4020-32. PubMed ID: 22992620
[TBL] [Abstract][Full Text] [Related]
35. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
Saatci Ö; Borgoni S; Akbulut Ö; Durmuş S; Raza U; Eyüpoğlu E; Alkan C; Akyol A; Kütük Ö; Wiemann S; Şahin Ö
Oncogene; 2018 Apr; 37(17):2251-2269. PubMed ID: 29391599
[TBL] [Abstract][Full Text] [Related]
36. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer.
Shi SJ; Wang LJ; Yu B; Li YH; Jin Y; Bai XZ
Oncotarget; 2015 May; 6(13):11652-63. PubMed ID: 25871474
[TBL] [Abstract][Full Text] [Related]
37. circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer.
Ling Y; Liang G; Lin Q; Fang X; Luo Q; Cen Y; Mehrpour M; Hamai A; Liu Z; Shi Y; Li J; Lin W; Jia S; Yang W; Liu Q; Song E; Li J; Gong C
Mol Cancer; 2022 Jan; 21(1):8. PubMed ID: 34980129
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
39. Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors.
Yeh ES; Abt MA; Hill EG
Breast Cancer Res Treat; 2015 Jan; 149(1):91-8. PubMed ID: 25515931
[TBL] [Abstract][Full Text] [Related]
40. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
